4Q Loss: $1.6 billion (earnings were $411 million 4Q25) ...

ADARx Pharmaceuticals has named Donald Fong, MD, its new Chief Medical Officer (CMO). He served in the same post at BioCryst Pharmaceuticals.

Revenues up 7% in the quarter despite €801 million loss.

Braveheart Bio is naming Marc Evanchik Chief Scientific Officer (CSO) and appointing Brittany de Temple Senior Vice President ...

AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...

Sales growth was driven by both US Operations and International Operations. The volume growth of the global branded GLP-1 ...

Driven by the growing prevalence of chronic diseases, the need for convenient and cost-effective drug delivery solutions, and ...

OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS’ CAR-T programs.

Pharmaceutical sales were $14.8 billion, up 6% in the quarter. Comments: Pharmaceutical sales were $14.8 billion, up 6%. The increase was primarily driven by growth in oncology as well as ...

Biomica, a subsidiary of Evogene, and Lishan Biotech have agreed to a worldwide, exclusive licensing deal for a microbiome-based therapeutic.

In 2026, some of the key industry trends essential to company success and maintaining stability include long-lasting ...

Charles River Laboratories will close its cell therapy contract development and manufacturing site in Hanover, Md., ...